Analysis of the efficacy and safety of erythropoietin for anemia in patients with chronic heart failure
10.3760/cma.j.issn.1008-6706.2012.07.021
- VernacularTitle:促红细胞生成素对慢性心功能不全合并贫血患者的疗效及安全性分析
- Author:
Mingsheng LI
;
Lina CHEN
- Publication Type:Journal Article
- Keywords:
Ventricular dysfunction;
Anemia,hypochromic;
Erythropoietin;
Treatment outcome
- From:
Chinese Journal of Primary Medicine and Pharmacy
2012;19(7):1003-1004
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo analyze the efficacy and safety of erythropoietin for anemia in patients with chronic heart failure.Methods66 cases with chronic heart failure were randomly divided into the observation group and the control group.The control group was treated with conventional anti-anemia iron treatment,and the observation group was taken erythropoietin therapy treatment on the basis of the control group.Both of the two groups were treated for 8 weeks continuously.ResultsThere were statistically significant differences between the two groups of patients after 8 weeks of treatment,cardiac function had improvement after treatment than before treatment (P ＜ 0.05 ).The observation group was significantly superior than the control group.The blood data in the two groups were compared,the Hb,RBC of the observation group were significantly increased compared with before treatment,the difference was significant (P ＜ 0.05).The RBC level did not change significantly in the control group before and after treatment.The electronic patient data in the two groups were compared,the LVEF,FS in the observation group and control group improved significantly compared with before treatment,but improvement of the observation group was significantly better than control group.The degree of improvement in the two groups were compared,the difference was significant( P ＜0.05).The SV,CO in the two groups were compared,it increasedsignificantly than before treatment,the difference was significant(P ＜ 0.05).The SV,CO before and after treatment in the control group didn't improve significantly.The E/A before and after treatment didn't improve significantly.The incidence of adverse drug reactions in the two groups showed no significant difference.ConclusionThe level of anemia had a direct impact on the degree of heart function classification.Following the usual treatment of heart failure,taking erythropoietin for anemia in patients with chronic heart treatment could significantly improve the treatment of patients with curative effect,with the advantages of safe,widely used for clinical application.
